IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Immunocore Holdings plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$29.84+0.44 (+1.50%)
Close on Oct 19, 2026
- Market cap
- $1.52B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Share price
−$3.72 (−11.08%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Immunocore Holdings plc grew revenue 21.0% to $430.78M over the twelve months to Jun 30, 2026. Free cash flow was -$41.15M, down 244.6% from a year earlier.
Revenue
$430.78M
+21.0% vs. a year earlier
Operating income
-$22.58M
TTM Q2 2026
Free cash flow
-$41.15M
-244.6% vs. a year earlier
EPS, diluted
-$0.36
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.52B
- P/E ratio
- –
- Price to sales
- 3.53
- Price to book
- 3.62
- Dividend yield
- 0.00%
- Free cash flow yield
- -2.71%
Fundamentals
- Revenue
- $430.78M
- Net income
- -$18.07M
- EPS, diluted
- -$0.36
- Free cash flow
- -$41.15M
- Book value per share
- $8.24
- Diluted shares
- 51M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$430.78M+21.0% YoY
Gross profit
$426.04M+20.5% YoY
Operating income
-$22.58M
Net income
-$18.07M
EPS, diluted
-$0.36
Free cash flow
-$41.15M-244.6% YoY
Reported periodTrailing twelve months